China’s pharma industry has become adept at innovation, but developing companies to challenge the big multinationals is proving even harder.
A worker takes samples at the raw material workshop of Hengrui's biomedical industrial park in Lianyungang, Jiangsu, China, December 13, 2021. Credit: Wang Jianmin/Costfoto/Future Publishing via Getty Images
For China’s biopharma industry, discovering new drugs is one matter: developing and selling them globally is another.
In recent years, top
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
In an extract from their new book, The Bitter Struggle, two former U.S. government officials describe how the Biden administration sought to control outsourcing of leading American AI technologies and prevent their possible leakage to China.
The writer and historian talks about his new book on the key men and women that have influenced America’s approach to China over the last century, and the dangers of ‘groupthink’ among China hands.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
